Idiopathic Hypersomnia Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
Verified date | February 2024 |
Source | Harmony Biosciences, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with idiopathic hypersomnia (IH) age ≥18 years. Key secondary objectives of this study are to assess the impact of pitolisant on: - Overall symptoms of IH - Patient impression of overall change in their symptoms of IH - Investigator assessment of overall disease severity of IH Other secondary objectives of this study are to assess the impact of pitolisant in patients with IH on: - Patient impression of overall severity of their EDS - Functional status and activities of daily living - Sleep-related impairment - Sleep inertia - Cognitive function
Status | Completed |
Enrollment | 214 |
Est. completion date | September 8, 2023 |
Est. primary completion date | September 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Is able to provide voluntary, written informed consent. 2. Has a current diagnosis of IH per International Classification of Sleep Disorders Third Edition (ICSD 3) criteria. 3. Male or female patient age =18 years at the time of Screening. 4. Has an ESS score of =12 at Screening and at Baseline (Visit 2). 5. Has a PGI-S score of moderate, severe, or very severe at Screening and at Baseline (Visit 2). 6. For patients being treated for OSA or other hypoventilatory conditions, patients must be compliant as demonstrated by BiPAP/CPAP therapy with 30 days of data showing =4 hours of BiPAP/CPAP therapy per night for =70% of nights. If not on BiPAP/CPAP therapy, patients being treated for OSA must be compliant as determined by the Investigator with their medical device or oral appliance. Data must be from within 90 days prior to the Screening visit. Patients must agree to maintain compliance with their treatment for OSA throughout the duration of the study. 7. If on a treatment that could affect daytime sleepiness (including but not limited to oxybates, stimulants, modafinil, and armodafinil): 1. Must be on a stable dose for at least 2 months prior to Screening and agree to continue the stable dose for the duration of the study. 2. If not on a stable dose for 2 months prior to Screening, washout for 5 half-lives or 14 days, whichever is longer, prior to Day 1 and agree to remain off these treatments until completion of the study. 8. A patient who is a female of child-bearing potential (FCBP) must have a negative serum pregnancy test at the Screening Visit and negative urine pregnancy test at the Baseline Visit (Visit 2) and at the end of the Stable Dose Period (Visit 4) and agree to remain abstinent or use an effective method of non-hormonal contraception to prevent pregnancy for the duration of the study and for 21 days after final dose of study drug. 9. Must have a negative result on urine drug screen at the Screening Visit, Baseline Visit (Visit 2) and at the end of the Stable Dose Period (Visit 4), except for medications that are prescribed by a healthcare provider for medical conditions. 10. In the opinion of the Investigator, the patient is capable of understanding and complying with the protocol and administration of oral study drug. Exclusion Criteria: 1. Has hypersomnia due to another medical disorder (e.g., narcolepsy). 2. Has an AHI of =10 as determined by the most recent sleep study or BiPAP/CPAP device readout. 3. Has a clinically significant hypoventilatory condition as determined by the Investigator. 4. Has a primary diagnosis of a psychiatric illness that is not well controlled. 5. Patients taking antidepressants who have not been on a stable dose of their antidepressant for at least 12 weeks prior to Screening; patients on a stable dose of their antidepressant for at least 12 weeks prior to Screening must agree to continue their stable dose for the duration of the study. 6. Experiences a mean of <6 hours of sleep per night based on sleep diary during Screening (patients need to record at least 7 nights within a 10-day period in their sleep diary within 14-days prior to the Baseline Visit [Visit 2]). 7. Consistently consumes >600 mg of caffeine per day and is unable/unwilling to reduce caffeine intake to =600 mg per day for the duration of the study. 8. Does not agree to discontinue any prohibited medication or substance listed in the protocol. 9. Is currently or has previously used pitolisant. 10. Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study and for 21 days after final dose of study drug. 11. Participation in an interventional research study involving another investigational medication, device, or behavioral treatment within 28 days or within 5 half-lives of the investigational medication (whichever is longer) prior to Screening. 12. Has a diagnosis of ESRD (estimated glomerular filtration rate [eGFR] of <15 mL/minute/1.73 m²) or severe hepatic impairment (Child-Pugh C). 13. Has a diagnosis of moderate or severe renal impairment (eGFR =15 to =59 mL/minute/1.73 m²) or moderate hepatic impairment (Child-Pugh B) at Screening or at any time during the study. 14. Has a history of long corrected QT interval (QTc) syndrome or corrected QT interval using Fridericia's formula (QTcF) >450 msec for males or >470 msec for females (QTcF = QT / 3v RR) at Screening. 15. Is receiving and is unable to discontinue a medication known to prolong the QT interval. 16. Is receiving a concomitant medication that is known to be a strong CYP3A4 inducer, or a centrally acting histamine 1 (H1) receptor antagonist; patients who undergo a washout of these medications of at least 5 half-lives or one week (whichever is longer) may be enrolled in the study. Use of strong CYP2D6 inhibitors is allowed; however, for these patients the maximum permitted daily dose of pitolisant is 17.8 mg. 17. Is a known CYP2D6 poor metabolizer (PM). 18. Has abnormal laboratory values at Screening that are clinically significant as determined by the Investigator. 19. Has initiated any new or change in allied health therapies or interventions that can interfere with the study outcomes within 28 days prior to Screening and at any time during the study, based on the Investigator's judgment. 20. Has a current or recent (within 1 year) history of a substance use disorder or dependence disorder, including alcohol, tobacco, and caffeine use disorders as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). 21. Has planned surgery during the study. 22. Has a significant risk of committing suicide or suicidality based on history; routine psychiatric examination; Investigator's judgment; or an answer of "yes" on any question other than questions 1 to 3 (for the previous month) or "yes" on any question in the suicidal behavior section (for the past year) of the Columbia-Suicide Severity Scale (C-SSRS), Baseline/Screening. 23. Based on the judgment of the Investigator, is unsuitable for the study for any reason, including but not limited to an unstable or uncontrolled medical condition or one that might interfere with the conduct of the study, confound interpretation of study results, pose a health risk to the patient, or compromise the integrity of the study. This exclusion criterion applies not only to entry into the study, but also to continuation in the study, should such an unstable, uncontrolled, or serious medical condition arise. |
Country | Name | City | State |
---|---|---|---|
United States | CardioVoyage | Ardmore | Oklahoma |
United States | Neurotrials Research Inc. | Atlanta | Georgia |
United States | FutureSearch Trials of Neurology LP | Austin | Texas |
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Alpine Clinical Research Center | Boulder | Colorado |
United States | Meris Clinical Research | Brandon | Florida |
United States | NeuroScience Research Center, LLC | Canton | Ohio |
United States | Medical University of South Carolina- Institute of Psychiatry | Charleston | South Carolina |
United States | Advanced Center for Sleep Disorders | Chattanooga | Tennessee |
United States | St. Luke's Sleep Medicine and Research Center | Chesterfield | Missouri |
United States | Helene A. Emsellem MD PC | Chevy Chase | Maryland |
United States | Northwestern University | Chicago | Illinois |
United States | Intrepid Research, LLC | Cincinnati | Ohio |
United States | St. Francis Medical Institute | Clearwater | Florida |
United States | Cleveland Clinc | Cleveland | Ohio |
United States | Rainbow Babies Children's Hospital | Cleveland | Ohio |
United States | Bogan Sleep Consultants | Columbia | South Carolina |
United States | Neurology Clinic, P.C. | Cordova | Tennessee |
United States | Research Carolina Elite LLC | Denver | North Carolina |
United States | Ohio Sleep Medicine and Neuroscience Institue | Dublin | Ohio |
United States | Duke University School of Medicine | Durham | North Carolina |
United States | Minnesota Lung Center | Edina | Minnesota |
United States | The Neurological Center of North GA | Gainesville | Georgia |
United States | Clinical Research of Gastonia | Gastonia | North Carolina |
United States | NorthShore Uni HealthSys-Glenbrook Hospital | Glenview | Illinois |
United States | ARSM Research | Huntersville | North Carolina |
United States | Cedars-Sinai Medical Towers | Los Angeles | California |
United States | University of California- Los Angeles | Los Angeles | California |
United States | University of Wisconsin-Madison | Madison | Wisconsin |
United States | Sleep Medicine Specialists of South Florida, PA | Miami | Florida |
United States | North Star Medical Research | Middleburg | Ohio |
United States | West Virginia University - Department of Neurology | Morgantown | West Virginia |
United States | Northwell Health | New Hyde Park | New York |
United States | Neurocare, INC | Newton | Massachusetts |
United States | Children's Hospital of the King's Daughter | Norfolk | Virginia |
United States | Lowcountry Lung Critical Care | North Charleston | South Carolina |
United States | Great Plains Health | North Platte | Nebraska |
United States | Norwalk Hospital Sleep Center | Norwalk | Connecticut |
United States | Henry Ford Health System | Novi | Michigan |
United States | Brian Abaluck, LLC | Paoli | Pennsylvania |
United States | OSF HealthCare Saint Francis Medical Center | Peoria | Illinois |
United States | Phoenix Medical Group | Peoria | Arizona |
United States | Bronson Sleep Health | Portage | Michigan |
United States | Central Texas Neurology Consultants, PA | Round Rock | Texas |
United States | Clayton Sleep Institute | Saint Louis | Missouri |
United States | Pasadena Center For Medical Research, LLC | Saint Petersburg | Florida |
United States | Sleep Medicine Specialists of California | San Ramon | California |
United States | SDS Clinical Trials Inc. | Santa Ana | California |
United States | Santa Monica Clinical Trials | Santa Monica | California |
United States | Mayo Clinic | Scottsdale | Arizona |
United States | Clinical Neurophysiology Services | Sterling Heights | Michigan |
United States | Comprehensive Sleep Medicine Associates | Sugar Land | Texas |
United States | Northwest Houston Neurology and Sleep | Tomball | Texas |
United States | Neurology Specialists of Monmouth County, PA | West Long Branch | New Jersey |
United States | Abington Neurological Associates | Willow Grove | Pennsylvania |
United States | Florida Pediatric Research Institute | Winter Park | Florida |
United States | Minnesota Lung Center | Woodbury | Minnesota |
United States | Respiratory Specialists | Wyomissing | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Harmony Biosciences, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Excessive Daytime Sleepiness | Change in Epworth Sleepiness Scale score from the end of the Stable Dose Period to the end of the 4-week Double-Blind Randomized Withdrawal Phase for pitolisant compared with placebo.
The score of the Epworth Sleepiness Scale ranges from 0 to 24. A decrease in score represents an improvement in excessive daytime sleepiness. |
Week 8 to Week 12 | |
Secondary | Symptoms of idiopathic hypersomnia | Change in Idiopathic Hypersomnia Severity Scale.
The score of the Idiopathic Hypersomnia Severity Scale ranges from 0 to 50. A decrease in score represents an improvement in symptoms of idiopathic hypersomnia. |
Week 8 to Week 12 | |
Secondary | Symptoms of idiopathic hypersomnia | Percent of patients who worsen on the Patient Global Impression of Change.
The Patient Global Impression of Change is a five item scale that ranges from much better to much worse. An assessment of being better represents an improvement in the patient's overall perception of the change in their idiopathic hypersomnia. |
Week 8 to Week 12 | |
Secondary | Symptoms of idiopathic hypersomnia | Change in Clinical Global Impression of Severity.
The Clinical Global Impression of Severity is a five item scale that ranges from none to very severe. An assessment of less severe symptoms represents an improvement in the clinician's perception of the patient's overall clinical status related to idiopathic hypersomnia. |
Week 8 to Week 12 | |
Secondary | Symptoms of idiopathic hypersomnia | Change in Patient Global Impression of Severity of their excessive daytime sleepiness.
The Patient Global Impression of Severity is a five item scale that ranges from none to very severe. An assessment of less severe symptoms represents an improvement in the patient's perception of the severity of their excessive daytime sleepiness. |
Week 8 to Week 12 | |
Secondary | Functional outcomes of sleep | Change in Functional Outcomes of Sleep Questionnaire 10-item Version.
The score of the Functional Outcomes of Sleep Questionnaire 10-item Version ranges from 5 to 20. An increase in score represents an improvement in the patient's impression of the impact of hypersomnia on multiple activities of everyday living. |
Week 8 to Week 12 | |
Secondary | Sleep related impairments during wakefulness | Change in Patient-Reported Outcomes Measurement Information System, Sleep-Related Impairment.
The score of the Patient-Reported Outcomes Measurement Information System, Sleep-Related Impairment ranges from 8 to 40. A decrease in score represents an improvement in the patient's impression of the impact of hypersomnia on multiple activities of everyday living. |
Week 8 to Week 12 | |
Secondary | Sleep inertia | Change in Sleep Inertia Questionnaire.
The Sleep Inertia Questionnaire ranges from 21 to 105. A decrease in score represents an improvement in the patient's ability to wake up after sleep. |
Week 8 to Week 12 | |
Secondary | Working Memory | Change in Cogstate One Back Test.
The Cogstate One Back Test is a computerized test. A faster speed represents a better working memory test performance. |
Week 8 to Week 12 | |
Secondary | Attention | Change in Cogstate Identification Test.
The Cogstate Identification Test is a computerized test. A faster speed represents an improvement in attention test performance. |
Week 8 to Week 12 | |
Secondary | Psychomotor Function | Change in Cogstate Detection Test.
The Cogstate Detection Test is a computerized test. A faster speed represents an improvement in psychomotor test performance. |
Week 8 to Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04026958 -
Clarithromycin Mechanisms in Hypersomnia Syndromes
|
Phase 2 | |
Completed |
NCT02512588 -
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
|
Phase 2 | |
Completed |
NCT01183312 -
Flumazenil for the Treatment of Primary Hypersomnia
|
Phase 1/Phase 2 | |
Completed |
NCT03597555 -
Sodium Oxybate in Idiopathic Hypersomnia
|
Phase 2/Phase 3 | |
Completed |
NCT03356938 -
The Role of the Circadian System in Neurological Sleep-wake Disorders
|
N/A | |
Completed |
NCT03533114 -
A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
|
Phase 3 | |
Active, not recruiting |
NCT03542851 -
A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia
|
Phase 2 | |
Enrolling by invitation |
NCT05371483 -
Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
|
||
Not yet recruiting |
NCT06252571 -
a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial
|
Phase 2 | |
Completed |
NCT04827329 -
Anesthetic Management of Patients With Chronic Sleep Disorders
|
||
Not yet recruiting |
NCT06457945 -
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
|
N/A | |
Recruiting |
NCT05875974 -
Ph4 PSG Combined JZP258-407
|
Phase 4 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Completed |
NCT01146600 -
Clarithromycin for the Treatment of Hypersomnia
|
Phase 2 | |
Recruiting |
NCT04330963 -
International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
|
||
Completed |
NCT04091438 -
A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
|
Phase 1 | |
Recruiting |
NCT05615584 -
Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence
|
N/A | |
Recruiting |
NCT05837091 -
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
|
Phase 4 | |
Recruiting |
NCT05321355 -
Mainz Register of Patients With Sleep Disorders
|
||
Active, not recruiting |
NCT05668754 -
Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH
|
Phase 2 |